Edit ID | Edit Comment | Time | |
---|---|---|---|
402308 | updating DNMT3A interp | 11/12/2018 3:41 PM |
DNMT3A is a DNA methyltransferase. Recurrent, somatic, heterozygous mutations in DNMT3A have been reported in approximately 18-25% of cases of acute myeloid leukemia, 8% of cases of myelodysplastic syndrome, up to 15% of myeloproliferative neoplasms and less than 5% of cases of chronic myelomonocytic leukemia. Mutations in DNMT3A have been reported to occur together with mutations in other genes including JAK2, FLT3, IDH1/IDH2, ASXL1, TET2 and NPM1. DNMT3A mutations have been associated with reduced enzymatic activity or altered histone binding, as well as reduced DNA methylation in various genomic regions and altered gene expression in some models. DNMT3A mutations may be associated with adverse prognosis . In addition to myeloid disorders, mutations in DNMT3A have also been reported in approximately 15% of cases of adult, eary T cell precursor acute lymphoblastic leukemia.
DNMT3A is a DNA methyltransferase. Recurrent, somatic, heterozygous mutations in DNMT3A have been reported in approximately 18-25% of cases of acute myeloid leukemia, 8% of cases of myelodysplastic syndrome, up to 15% of myeloproliferative neoplasms, less than 5% of cases of chronic myelomonocytic leukemia and 15% of cases of adult, eary T cell precursor acute lymphoblastic leukemia. Mutations in DNMT3A have been reported to occur together with mutations in other genes including JAK2, FLT3, IDH1/IDH2, ASXL1, TET2 and NPM1. DNMT3A mutations have been associated with reduced enzymatic activity or altered histone binding, as well as reduced DNA methylation in various genomic regions and altered gene expression in some models. Codon 882 is a hotspot for mutations in DNMT3A. DNMT3A mutations may be associated with adverse prognosis in some types of AML according to some studies.